aUroCell-Tx
Sponsors
Phosprint P.C., Phosprint S.A.
Conditions
Muscle-invasive bladder cancer (MIBC) patientseligible for neobladder reconstruction following radical cystectomyeligible for neobladder reconstruction following radical cystectomy.Μuscle-invasive bladder cancer (MIBC) patients
Phase 1
An Exploratory, First-in-Human, study to investigate the safety and preliminary efficacy of InvivoLPrint-U-Therapy, a combination of an advanced therapy medicinal product (ATMP) of expanded autologous urothelial cells with an in vivo bioprinter for administration during orthotopic neobladder surgery
Not yet recruitingCTIS2025-522963-14-00
Target: 6Updated: 2025-12-17
A follow-up extension study of patients who completed the U-LaserPrint-1 clinical trial to evaluate the long-term safety and efficacy of treatment with InvivoLPrint-U.
Not yet recruitingCTIS2026-527804-26-00
Target: 6Updated: 2026-09-17